A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
NCT05258110 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2026-03-30
Summary
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a recommended substrate of CYP3A4.
Conditions
- Healthy
Interventions
- DRUG
-
midazolam
midazolam
- DRUG
-
iclepertin (BI 425809)
BI 425809
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-03-18
- Primary Completion
- 2022-05-31
- Completion
- 2022-05-31
Countries
- Germany
Study Locations
More Related Trials
-
Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects
NCT03637049 ·Status: COMPLETED ·Phase: PHASE1
-
Drug-Drug Interaction Study: ASP2151 and Midazolam
NCT02403635 ·Status: COMPLETED ·Phase: PHASE1
-
Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)
NCT04865445 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)
NCT02254148 ·Status: COMPLETED ·Phase: PHASE1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers
NCT02204501 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
NCT02010970 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
NCT04411030 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin
NCT02345304 ·Status: WITHDRAWN ·Phase: PHASE1
-
Effect of Tepotinib on PK of CYP3A Substrate Midazolam
NCT03628339 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers
NCT05895266 ·Status: COMPLETED ·Phase: PHASE1
-
Drug Interaction Study of Isavuconazole and Midazolam
NCT01406171 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood
NCT05738291 ·Status: COMPLETED ·Phase: PHASE1
-
A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
NCT02147808 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Drug Interaction of ASP015K and Midazolam
NCT01182077 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects
NCT01402076 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects
NCT01989169 ·Status: COMPLETED ·Phase: PHASE1
-
Drug Interaction Study Between AZD3480 and Cytochrome P450
NCT00692510 ·Status: COMPLETED ·Phase: PHASE1
-
CKD-506 Drug-Drug Interaction Study in Healthy Male Subjects
NCT05238948 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects
NCT05070195 ·Status: COMPLETED ·Phase: PHASE1
-
TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.
NCT00866853 ·Status: COMPLETED ·Phase: PHASE1
-
Drug-Drug Interaction Study of Qualaquin and Midazolam
NCT00785486 ·Status: COMPLETED ·Phase: PHASE1
-
Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
NCT04138836 ·Status: COMPLETED ·Phase: PHASE1
-
Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants
NCT05937386 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants
NCT06547164 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects
NCT05480488 ·Status: COMPLETED ·Phase: PHASE1